ERBB2 and breast carcinoma: Currently, a trial (DAP-HER-02, NCT05328440) investigating first-line treatment for HER2+ advanced breast cancer with a combination of dalpiciclib and pyrotinib, along with fulvestrant or inetetamab, is currently underway.